CLINICAL TRIAL: PHASE II SAFETY AND IMMUNOGENICITY STUDY OF QUADRIVALENT HUMAN P

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究是为了评估人乳头瘤病毒(HPV)研究疫苗的安全性和效果。研究中的疫苗被称为人乳头状瘤病毒(6型、11型、16型、18型)L1病毒样颗粒[VLP]疫苗(qHPV疫苗，也称为Gardasil)。这项研究中使用的疫苗和安慰剂都将由默克研究实验室提供。这项研究将着眼于两件事。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is being done to evaluate the safety and effect of an investigational vaccine against human papilloma virus (HPV). The investigational vaccine is called Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle [VLP] Vaccine (QHPV Vaccine, also known as GARDASIL¿¿). Both the vaccine and placebo used in this study will be provided by Merck Research Laboratories. The study will look at two things.